<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05049720</url>
  </required_header>
  <id_info>
    <org_study_id>MDT20054</org_study_id>
    <nct_id>NCT05049720</nct_id>
  </id_info>
  <brief_title>ExtraVascular Implantable Cardiac Defibrillator Continued Access Study</brief_title>
  <acronym>EV ICD CA</acronym>
  <official_title>ExtraVascular Implantable Cardiac Defibrillator Continued Access Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to provide continued access to the Extravascular Implantable&#xD;
      Cardioverter Defibrillator (EV ICD) System.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll subjects who are indicated to receive an implantable defibrillator who&#xD;
      meet all of the inclusion criteria and none of the exclusion criteria. Subjects will receive&#xD;
      an investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system, in&#xD;
      which a lead is placed outside of the heart and veins to deliver defibrillation therapy.&#xD;
      Subjects will be followed every 6 months following system implantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">July 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 28, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complications</measure>
    <time_frame>Through study completion, an average of 18 months</time_frame>
    <description>EV ICD system and/or procedure related adverse events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Tachycardia</condition>
  <condition>Ventricular Arrythmia</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be implanted with an Extravascular ICD and undergo requisite electrical testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Defibrillation using the Extravascular ICD</intervention_name>
    <description>VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient has a Class I or IIa indication for implantation of an ICD according to the&#xD;
             ACC/AHA/HRS Guidelines.[1]&#xD;
&#xD;
          2. Patient is willing and able to sign and date the Informed Consent Form for their&#xD;
             participation in the study.&#xD;
&#xD;
          3. Patient is at least 18 years of age and meets age requirements per local law.&#xD;
&#xD;
          4. Patient is geographically stable and willing and able to comply with the study&#xD;
             procedures and visits for the duration of the follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has indications for bradycardia pacing[2] or Cardiac Resynchronization Therapy&#xD;
             (CRT)[3] (Class I, IIa, or IIb indication).&#xD;
&#xD;
          2. Patients with an existing pacemaker, ICD, or CRT device or leads.&#xD;
&#xD;
          3. Patients with these medical interventions are excluded from participation in the&#xD;
             study:&#xD;
&#xD;
               -  Prior sternotomy&#xD;
&#xD;
               -  Any prior medical condition or procedure that leads to adhesions in the anterior&#xD;
                  mediastinal space (i.e., prior mediastinal instrumentation, mediastinitis)&#xD;
&#xD;
               -  Prior abdominal surgery in the epigastric region&#xD;
&#xD;
               -  Planned sternotomy&#xD;
&#xD;
               -  Prior chest radiotherapy&#xD;
&#xD;
             Or any other prior/planned medical intervention not listed that precludes their&#xD;
             participation in the opinion of the Investigator.&#xD;
&#xD;
          4. Patients with these medical conditions or anatomies are excluded from participation in&#xD;
             the study:&#xD;
&#xD;
               -  Hiatal hernia that distorts mediastinal anatomy&#xD;
&#xD;
               -  Marked sternal abnormality (e.g., pectus excavatum that impedes the substernal&#xD;
                  tunneling path or procedure)&#xD;
&#xD;
               -  Decompensated heart failure&#xD;
&#xD;
               -  COPD with oxygen dependence&#xD;
&#xD;
               -  Gross hepatosplenomegaly&#xD;
&#xD;
             Or any other known medical condition or anatomy type not listed that precludes their&#xD;
             participation in the opinion of the Investigator.&#xD;
&#xD;
          5. Patients with a medical condition that precludes them from undergoing defibrillation&#xD;
             testing:&#xD;
&#xD;
               -  Severe aortic stenosis&#xD;
&#xD;
               -  Current Intracardiac LA or LV thrombus&#xD;
&#xD;
               -  Severe proximal three-vessel or left main coronary artery disease without&#xD;
                  revascularization&#xD;
&#xD;
               -  Hemodynamic instability&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Recent stroke or transient ischemic attack (within the last 6 months)&#xD;
&#xD;
               -  Known inadequate external defibrillation&#xD;
&#xD;
               -  LVEF &lt; 20%&#xD;
&#xD;
               -  LVEDD &gt;70 mm&#xD;
&#xD;
             Or any other known medical condition not listed that precludes their participation in&#xD;
             the opinion of the Investigator.&#xD;
&#xD;
          6. Patient with any evidence of active infection or undergoing treatment for an&#xD;
             infection.&#xD;
&#xD;
          7. Patient is contraindicated from temporary suspension of oral/systemic anticoagulation.&#xD;
&#xD;
          8. Patient with current implantation of neurostimulator or any other chronically&#xD;
             implanted device that delivers current in the body.&#xD;
&#xD;
          9. Patient meets ACC/AHA/HRS or ESC clinical guideline Class III criteria for an ICD&#xD;
             (e.g., life expectancy of less than 12 months).&#xD;
&#xD;
         10. Patient is enrolled or planning to enroll in a concurrent clinical study that may&#xD;
             confound the results of this study, without documented pre-approval from a Medtronic&#xD;
             study manager.&#xD;
&#xD;
         11. Patient with any exclusion criteria as required by local law (e.g., age or other).&#xD;
&#xD;
         12. Pregnant women or breastfeeding women, or women of childbearing potential and who are&#xD;
             not on a reliable form of birth regulation method or abstinence*&#xD;
&#xD;
        (*If required by local law, women of child-bearing potential must undergo a pregnancy test&#xD;
        within seven days prior to EV ICD Continued Access Study procedures)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shenita Bolstrom</last_name>
    <phone>763.514.4000</phone>
    <email>shenita.bolstrom@medtronic.com</email>
  </overall_contact>
  <reference>
    <citation>Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018 Oct 2;72(14):e91-e220. doi: 10.1016/j.jacc.2017.10.054. Epub 2018 Aug 16. Review. Erratum in: J Am Coll Cardiol. 2018 Oct 2;72(14):1760.</citation>
    <PMID>29097296</PMID>
  </reference>
  <reference>
    <citation>Wilkoff BL, Fauchier L, Stiles MK, Morillo CA, Al-Khatib SM, Almendral J, Aguinaga L, Berger RD, Cuesta A, Daubert JP, Dubner S, Ellenbogen KA, Mark Estes NA 3rd, Fenelon G, Garcia FC, Gasparini M, Haines DE, Healey JS, Hurtwitz JL, Keegan R, Kolb C, Kuck KH, Marinskis G, Martinelli M, McGuire M, Molina LG, Okumura K, Proclemer A, Russo AM, Singh JP, Swerdlow CD, Teo WS, Uribe W, Viskin S, Wang CC, Zhang S. 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm. 2016 Feb;13(2):e50-86. doi: 10.1016/j.hrthm.2015.11.018. Epub 2015 Dec 1.</citation>
    <PMID>26607062</PMID>
  </reference>
  <reference>
    <citation>Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, Goldschlager NF, Hamilton RM, Joglar JA, Kim RJ, Lee R, Marine JE, McLeod CJ, Oken KR, Patton KK, Pellegrini CN, Selzman KA, Thompson A, Varosy PD. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019 Aug 20;74(7):e51-e156. doi: 10.1016/j.jacc.2018.10.044. Epub 2018 Nov 6. Erratum in: J Am Coll Cardiol. 2019 Aug 20;74(7):1016-1018.</citation>
    <PMID>30412709</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

